The short answer
Standardized extracts have small heterogeneous trials for vascular and symptom outcomes.
- Evidence and scope
- Mixed evidence
This status does not grade the ingredient for every goal, outcome, or person.
- Important limitation
- Trials are inconsistent or small, so a reliable clinically important benefit is not established.
- Before deciding
- Key concern: Anticoagulants, immunosuppressants, diabetes medicines, surgery, and autoimmune disease require review.
01 / PRACTICAL GUIDE
Dose, absorption, and combinations
These are indication-specific reference or studied ranges—not a personalized prescription. Start with the objective, then check the form, label, medicines, and health conditions.
Reference or studied range—not a personalized prescription. The product label or a clinician may specify a different dose.
Dose source ↗More is not automatically better. A clinician or product label may specify a different amount.
Not usefully classified as a fat- or water-soluble vitamin; absorption depends on the salt, extract, delivery system, and meal.
May be divided with meals.
Anticoagulants, immunosuppressants, diabetes medicines, surgery, and autoimmune disease require review.
Dose and use links lead to primary or official source material. Search links are discovery tools, not proof that every returned paper applies.
02 / EVIDENCE
What the research says
We keep supportive, mixed, negative, safety, and contextual findings together. The headline never replaces the underlying papers.
These are audited counts for this JIVANA collection, not search-result totals. Participants are counted once when multiple papers use the same cohort; review papers are not added again to participant totals.
Open the research timelineResearch timeline+
Entries are ordered by publication year. A study period appears only when the source reports it.
French maritime pine bark extract for chronic disorders
The trials were small, sparse within each condition, heterogeneous in outcomes, and at risk of bias. The review could not draw definitive efficacy or safety conclusions and found insufficient evidence to support use for any chronic disorder.
Study design and methods
- Design
- Cochrane systematic review of 15 randomized trials
- Population
- 791 children and adults across seven chronic disorders
- Intervention
- Standardized French maritime pine bark extract (Pycnogenol) versus placebo or other controls
- Outcome
- Condition-specific clinical outcomes, mortality, adverse events, and oxidative-stress biomarkers
Unscreened discovery appendix—not evidence46 candidate publicationsSearch run: Aug 21, 2026
Complete for the displayed PubMed query at the search timestamp—not for all databases or every possible synonym. Candidates can be irrelevant, duplicate the same study, or report negative findings. They are never summed as evidence or participants until screened.
03 / SOURCES
Start with the source material
The live search is for discovery only. Search-result counts change and are not included in the audited totals above.
Recent PubMed discovery recordsDirect links to the first 12 records returned by the reproducible search. These are discovery candidates—not reviewed summaries or a count of supportive findings.
- The Hypoglycaemic Effects of the New Zealand Pine Bark Extract on Sucrose Uptake and Glycaemic Responses in Healthy Adults-A Single-Blind, Randomised, Placebo-Controlled, Crossover Trial.Lim WXJ, Page RA, Gammon CS et al. · 2025 · Nutrients · PMID 40732901Open on PubMed ↗
- Impact of a Dietary Supplementation with French Maritime Pine Bark Extract Pycnogenol(®) on Salivary and Serum Inflammatory Biomarkers During Non-Surgical Periodontal Therapy-A Randomized Placebo-Controlled Double-Blind Trial.Bayer J, Petersen NK, Hess JV et al. · 2025 · Nutrients · PMID 40362854Open on PubMed ↗
- Does supplementation with pine bark extract improve cardiometabolic risk factors? A systematic review and meta-analysis.Mohammadi S, Fulop T, Khalil A et al. · 2025 · BMC complementary medicine and therapies · PMID 39987124Open on PubMed ↗
- Effect of a polyphenol-rich dietary supplement containing Pinus massoniana bark extract on blood pressure in healthy adults: A parallel, randomized placebo-controlled trial.Ferguson JJA, Oldmeadow C, Bentley D et al. · 2022 · Complementary therapies in medicine · PMID 36280012Open on PubMed ↗
- The effect of French maritime pine bark extract supplementation on inflammation, nutritional and clinical status in critically ill patients with traumatic brain injury: A randomized controlled trial.Malekahmadi M, Shadnoush M, Islam SMS et al. · 2021 · Phytotherapy research : PTR · PMID 34382717Open on PubMed ↗
- Complementary effects of pine bark extract supplementation on inattention, impulsivity, and antioxidative status in children with attention-deficit hyperactivity disorder: A double-blinded randomized placebo-controlled cross-over study.Hsu CD, Hsieh LH, Chen YL et al. · 2021 · Phytotherapy research : PTR · PMID 33559134Open on PubMed ↗
- Efficacy and safety of a supplement combination on hand pain among people with symptomatic hand osteoarthritis an internet-based, randomised clinical trial the RADIANT study.Liu X, Robbins S, Eyles J et al. · 2021 · Osteoarthritis and cartilage · PMID 33617972Open on PubMed ↗
- Effect of French maritime pine bark extract supplementation on metabolic status and serum vascular cell adhesion molecule-1 levels in patients with type 2 diabetes and microalbuminuria.Navval-Esfahlan E, Rafraf M, Asghari S et al. · 2021 · Complementary therapies in medicine · PMID 33610726Open on PubMed ↗
- A Placebo-Controlled, Pseudo-Randomized, Crossover Trial of Botanical Agents for Gulf War Illness: Curcumin (Curcuma longa), Boswellia (Boswellia serrata), and French Maritime Pine Bark (Pinus pinaster).Donovan EK, Kekes-Szabo S, Lin JC et al. · 2021 · International journal of environmental research and public health · PMID 33802272Open on PubMed ↗
- French maritime pine bark extract (pycnogenol) in association with triple combination cream for the treatment of facial melasma in women: a double-blind, randomized, placebo-controlled trial.Lima PB, Dias JAF, Esposito ACC et al. · 2021 · Journal of the European Academy of Dermatology and Venereology : JEADV · PMID 32841433Open on PubMed ↗
- Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.Cândido RCF, Menezes de Padua CA, Golder S et al. · 2021 · The Cochrane database of systematic reviews · PMID 33460048Open on PubMed ↗
- Oral Pycnogenol® Intake Benefits the Skin in Urban Chinese Outdoor Workers: A Randomized, Placebo-Controlled, Double-Blind, and Crossover Intervention Study.Zhao H, Wu J, Wang N et al. · 2021 · Skin pharmacology and physiology · PMID 33789311Open on PubMed ↗
04 / EXPERT CONTEXT
Expert context—not evidence
Expert positions are dated context—not scientific evidence. They never raise the evidence status or become consensus by repetition.
No direct, source-verified endorsement is currently recorded. Research authorship or discussion alone is not treated as endorsement.